Related Experiment Video
Updated: Jun 21, 2026
Semi-Minimal Invasive Method to Induce Myocardial Infarction in Rats and the Assessment of Cardiac Function by an Isolated Working Heart System
Published on: June 11, 2020
Simvastatin alleviates myocardial contractile dysfunction and lethal ischemic injury in rat heart independent of
A Adameova1, A Harcarova, J Matejikova
11Department of Pharmacology and Toxicology, Facultyof Pharmacy Comenius University, Bratislava, Slovak Republic.
Insights
Simvastatin protects hearts from ischemia-reperfusion injury by improving contractile recovery and reducing arrhythmias. These benefits occur independently of cholesterol reduction, suggesting other mechanisms are at play.
Area of Science:
- Cardiovascular Pharmacology
- Ischemia-Reperfusion Injury
Background:
- Statins (HMG-CoA reductase inhibitors) are widely used for coronary artery disease prevention due to cholesterol-lowering effects.
- The precise mechanisms by which statins protect against myocardial ischemia-reperfusion (I/R) injury, independent of cholesterol reduction, remain unclear.
Purpose of the Study:
- To investigate the cardioprotective effects of simvastatin against ischemia-reperfusion (I/R) injury in healthy and diabetic-hypercholesterolemic rat hearts.
- To determine if simvastatin's protective effects are mediated by cholesterol reduction or other mechanisms.
Main Methods:
- Rats (healthy and diabetic-hypercholesterolemic) received 5-day simvastatin treatment (10 mg/kg).
- Hearts were subjected to global ischemia/reperfusion or LAD coronary artery occlusion/reperfusion.
- Evaluated postischemic contractile dysfunction, ventricular arrhythmias, and infarct size (IS).
Main Results:
- Simvastatin significantly improved postischemic recovery of left ventricular developed pressure (LVDP) in both groups.
- Simvastatin abolished ventricular fibrillation and reduced ventricular tachycardia duration during reperfusion.
- Infarct size was significantly reduced by simvastatin in both healthy and diabetic-hypercholesterolemic rats.
- Simvastatin treatment did not alter plasma cholesterol levels in either group.
Conclusions:
- Simvastatin confers significant protection against myocardial I/R injury, improving contractile function and reducing arrhythmias.
- These cardioprotective effects are independent of simvastatin's cholesterol-lowering activity.
- Statins may exert beneficial effects through mechanisms other than HMG-CoA reductase inhibition.
Abstract:
Statins, the inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, are most frequently used drugs in the prevention of coronary artery disease due to their cholesterol-lowering activity. However, it is not exactly known whether these effects of statins or those independent of cholesterol decrease account for the protection against myocardial ischemia-reperfusion (I/R) injury. In this study, we investigated the effect of 5-day treatment with simvastatin (10 mg/kg) in Langendorff-perfused hearts of healthy control (C) and diabetic-hypercholesterolemic (D-H; streptozotocin + high fat-cholesterol diet, 5 days) rats subjected to 30-min global ischemia followed by 40-min reperfusion for the examination of postischemic contractile dysfunction and reperfusion-induced ventricular arrhythmias or to 30-min (left anterior descending) coronary artery occlusion and 2-h reperfusion for the infarct size determination (IS; tetrazolium staining). Postischemic recovery of left ventricular developed pressure (LVDP) in animals with D-H was improved by simvastatin therapy (62.7+/-18.2 % of preischemic values vs. 30.3+/-5.7 % in the untreated D-H; P<0.05), similar to the values in the simvastatin-treated C group, which were 2.5-fold higher than those in the untreated C group. No ventricular fibrillation occurred in the simvastatin-treated C and D-H animals during reperfusion. Likewise, simvastatin shortened the duration of ventricular tachycardia (10.2+/-8.1 s and 57.8+/-29.3 s in C and D-H vs. 143.6+/-28.6 s and 159.3+/-44.3 s in untreated C and D-H, respectively, both P<0.05). The decreased arrhythmogenesis in the simvastatin-treated groups correlated with the limitation of IS (in % of risk area) by 66 % and 62 % in C and D-H groups, respectively. However, simvastatin treatment decreased plasma cholesterol levels neither in the D-H animals nor in C. The results indicate that other effects of statins (independent of cholesterol lowering) are involved in the improvement of contractile recovery and attenuation of lethal I/R injury in both, healthy and diseased individuals.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System